These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 32616213)

  • 1. The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions.
    Drevets WC; Bhattacharya A; Furey ML
    Adv Pharmacol; 2020; 89():357-386. PubMed ID: 32616213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of muscarinic receptor mechanisms in antidepressant drug action.
    Witkin JM; Smith JL; Golani LK; Brooks EA; Martin AE
    Adv Pharmacol; 2020; 89():311-356. PubMed ID: 32616212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.
    Drevets WC; Zarate CA; Furey ML
    Biol Psychiatry; 2013 Jun; 73(12):1156-63. PubMed ID: 23200525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
    Furey ML; Drevets WC
    Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serendipity strikes again: scopolamine as an antidepressant agent in bipolar depressed patients.
    Janowsky DS
    Curr Psychiatry Rep; 2011 Dec; 13(6):443-5. PubMed ID: 21976067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antidepressant effects of anticholinergic drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2009 Jun; 47(6):17-20. PubMed ID: 19585799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interest of scopolamine as a treatment of major depressive disorder].
    Rigal A; Mouchabac S; Peretti CS
    Encephale; 2016 Dec; 42(6):568-573. PubMed ID: 27623122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
    Park L; Furey M; Nugent AC; Farmer C; Ellis J; Szczepanik J; Lener MS; Zarate CA
    Int J Neuropsychopharmacol; 2019 Jan; 22(1):10-18. PubMed ID: 30184133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scopolamine and depression: a role for muscarinic antagonism?
    Hasselmann H
    CNS Neurol Disord Drug Targets; 2014; 13(4):673-83. PubMed ID: 24938776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition.
    Johnson CR; Kangas BD; Jutkiewicz EM; Winger G; Bergman J; Coop A; Woods JH
    J Pharmacol Exp Ther; 2021 Jun; 377(3):336-345. PubMed ID: 33712507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scopolamine as an antidepressant: a systematic review.
    Jaffe RJ; Novakovic V; Peselow ED
    Clin Neuropharmacol; 2013; 36(1):24-6. PubMed ID: 23334071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice.
    Podkowa K; Pilc A; Podkowa A; Sałat K; Marciniak M; Pałucha-Poniewiera A
    Neuropharmacology; 2018 Oct; 141():214-222. PubMed ID: 30145321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine.
    Witkin JM; Overshiner C; Li X; Catlow JT; Wishart GN; Schober DA; Heinz BA; Nikolayev A; Tolstikov VV; Anderson WH; Higgs RE; Kuo MS; Felder CC
    J Pharmacol Exp Ther; 2014 Nov; 351(2):448-56. PubMed ID: 25187432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.
    Pilc A; Machaczka A; Kawalec P; Smith JL; Witkin JM
    Expert Opin Drug Discov; 2022 Oct; 17(10):1131-1146. PubMed ID: 35934973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors.
    Navarria A; Wohleb ES; Voleti B; Ota KT; Dutheil S; Lepack AE; Dwyer JM; Fuchikami M; Becker A; Drago F; Duman RS
    Neurobiol Dis; 2015 Oct; 82():254-261. PubMed ID: 26102021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.
    Guo W; Machado-Vieira R; Mathew S; Murrough JW; Charney DS; Grunebaum M; Oquendo MA; Kadriu B; Akula N; Henter I; Yuan P; Merikangas K; Drevets W; Furey M; Mann JJ; McMahon FJ; Zarate CA; Shugart YY
    Transl Psychiatry; 2018 Dec; 8(1):280. PubMed ID: 30552317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial.
    Miravalles C; Kane R; McMahon E; McDonald C; Cannon DM; Hallahan B
    Trials; 2022 Apr; 23(1):339. PubMed ID: 35461262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
    Gerhard DM; Wohleb ES; Duman RS
    Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Effect of Novel Antidepressant Drugs Acting at Specific Receptors of Neurotransmitters and Neuropeptides.
    Werner FM; Coveñas R
    Curr Pharm Des; 2019; 25(4):388-395. PubMed ID: 30969164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics.
    Dulawa SC; Janowsky DS
    Mol Psychiatry; 2019 May; 24(5):694-709. PubMed ID: 30120418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.